Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
- PMID: 35162972
- PMCID: PMC8835123
- DOI: 10.3390/ijms23031049
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
Abstract
SARS-CoV-2 uses the human cell surface protein angiotensin converting enzyme 2 (ACE2) as the receptor by which it gains access into lung and other tissue. Early in the pandemic, there was speculation that a number of commonly used medications-including ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs)-have the potential to upregulate ACE2, thereby possibly facilitating viral entry and increasing the severity of COVID-19. We investigated the influence of the NSAIDS with a range of cyclooxygenase (COX)1 and COX2 selectivity (ibuprofen, flurbiprofen, etoricoxib) and paracetamol on the level of ACE2 mRNA/protein expression and activity as well as their influence on SARS-CoV-2 infection levels in a Caco-2 cell model. We also analysed the ACE2 mRNA/protein levels and activity in lung, heart and aorta in ibuprofen treated mice. The drugs had no effect on ACE2 mRNA/protein expression and activity in the Caco-2 cell model. There was no up-regulation of ACE2 mRNA/protein expression and activity in lung, heart and aorta tissue in ibuprofen-treated mice in comparison to untreated mice. Viral load was significantly reduced by both flurbiprofen and ibuprofen at high concentrations. Ibuprofen, flurbiprofen, etoricoxib and paracetamol demonstrated no effects on ACE2 expression or activity in vitro or in vivo. Higher concentrations of ibuprofen and flurbiprofen reduced SARS-CoV-2 replication in vitro.
Keywords: ACE protein expression; ACE2 activity; ACE2 mRNA expression; NSAIDs; SARS-CoV-2 infection; ibuprofen.
Conflict of interest statement
The authors P.R., A.S., D.B., S.T., J.C., S.C., N.d.B., P.G., A.K., S.S. (Susanne Schiffmann), declare no competing interests. The authors B.C., S.S. (Simon Sinclair), I.L., G.P., W.F.L. are employees of Reckitt, the owners and distributors of the Nurofen brand.
Figures




Similar articles
-
A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.FASEB J. 2021 Mar;35(3):e21419. doi: 10.1096/fj.202100016R. FASEB J. 2021. PMID: 33566370 Free PMC article.
-
Cigarette Smoke Stimulates SARS-CoV-2 Internalization by Activating AhR and Increasing ACE2 Expression in Human Gingival Epithelial Cells.Int J Mol Sci. 2021 Jul 18;22(14):7669. doi: 10.3390/ijms22147669. Int J Mol Sci. 2021. PMID: 34299289 Free PMC article.
-
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.Cardiovasc Diabetol. 2021 Apr 27;20(1):90. doi: 10.1186/s12933-021-01275-w. Cardiovasc Diabetol. 2021. PMID: 33906662 Free PMC article.
-
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021. Front Immunol. 2021. PMID: 35003058 Free PMC article. Review.
-
The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.Tumour Biol. 2021;43(1):177-196. doi: 10.3233/TUB-200084. Tumour Biol. 2021. PMID: 34420993 Review.
Cited by
-
Harnessing immunity: Immunomodulatory therapies in COVID-19.World J Virol. 2024 Jun 25;13(2):92521. doi: 10.5501/wjv.v13.i2.92521. World J Virol. 2024. PMID: 38984079 Free PMC article. Review.
-
Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions.Microorganisms. 2023 Dec 11;11(12):2959. doi: 10.3390/microorganisms11122959. Microorganisms. 2023. PMID: 38138102 Free PMC article. Review.
-
Ibuprofen, other NSAIDs and COVID-19: a narrative review.Inflammopharmacology. 2023 Oct;31(5):2147-2159. doi: 10.1007/s10787-023-01309-7. Epub 2023 Aug 21. Inflammopharmacology. 2023. PMID: 37603158 Free PMC article. Review.
-
Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data.ACS Omega. 2024 Feb 14;9(8):8923-8939. doi: 10.1021/acsomega.3c06968. eCollection 2024 Feb 27. ACS Omega. 2024. PMID: 38434903 Free PMC article.
-
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.Signal Transduct Target Ther. 2023 Jun 7;8(1):237. doi: 10.1038/s41392-023-01510-8. Signal Transduct Target Ther. 2023. PMID: 37286535 Free PMC article. Review.
References
-
- Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–280. doi: 10.1016/j.cell.2020.02.052. - DOI - PMC - PubMed
-
- Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5. - DOI - PMC - PubMed
-
- Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Yee N.T.S., Liu C., Nerurkar S.N., Kai J.C.Y., et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J. Med. Virol. 2021;93:1449–1458. doi: 10.1002/jmv.26424. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous